Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

AACR Special Conference on Endometrial Cancer: New Biology Driving Research and Treatment

Award Number: R13CA254055
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2021

Group Awards By:

View Award Description

AACR Special Conference on Endometrial Cancer: New Biology Driving Research and Treatment - PROJECT SUMMARY The proposed conference, entitled “Endometrial Cancer: New Biology Driving Research and Treatment,” will be held November 7-9, 2020 in Miami, Florida. This will be the first AACR conference focused specifically on advances in endometrial cancer (EC). Over the last decade, the incidence of EC has been increasing globally. If current trends continue, in the United States the incidence of EC will double by 2030. Furthermore, the number of women dying from EC has also been increasing disproportionately to the rise in incidence, with rates exceeding those seen for most other solid tumors. There are few therapeutic options for women diagnosed with recurrent or metastatic EC, and median overall survival (OS) is short. No new agents have been approved for the treatment of EC in the past two decades. Emerging molecular knowledge of EC has led to clinical trials testing actionable events in molecularly defined recurrent EC patient populations. Molecular subtypes of EC have been well defined by The Cancer Genome Atlas Program and are now being incorporated into clinical trials and transitioned into clinical practice. Tangentially, based on these studies, the FDA has approved therapies based on microsatellite instability and mutational burden. Many emerging therapies are based on molecular characterization of EC in addition to histologic subtypes. There are also many cooperative group clinical trials completed, in progress, and approved for EC using novel biologic approaches. This suggests that numerous opportunities exist for diagnostics, prognostics, and therapeutics that would benefit from an AACR special conference. To this end, the AACR is seeking support to expand the conference and to recruit outstanding young investigators through additional travel awards. Attendance by this “next generation” of cancer scientists and caregivers will help better disseminate the rapidly growing collection of research innovations as well as ignite powerful collaborations. The program has been carefully designed to feature thought-provoking sessions on molecular stratification, DNA repair and replication, functional genomics and proteomics, novel model systems, immunotherapy, and targeted therapies. Collaboration and networking will be encouraged by incorporating multiple opportunities for education, thoughtful discussion, and meaningful interaction between participants.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	AMERICAN ASSN FOR CANCER RES	615 CHESTNUT ST FL 17	PHILADELPHIA	PA	19106	PHILADELPHIA	USA	Cancer Biology Research	000	1	12/23/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $5,000 )
2020	2020	AMERICAN ASSN FOR CANCER RES	615 CHESTNUT ST FL 17	PHILADELPHIA	PA	19106	PHILADELPHIA	USA	Cancer Biology Research	000	1	8/31/2020	NEW	$5,000
														Subtotal = $5,000

Grand Total All Awards = $5,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

AACR Special Conference on Endometrial Cancer: New Biology Driving Research and Treatment

Award Number: R13CA254055

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer